

Uveitic & Neurological manifestations



Maha Youssef, MD
Assistant Professor Ophthalmology,
Cairo University

CNS Diseases and Uveitis

Pia Allegri¹, MD; Roberto Rissotto², MD; Carl P. Herbert^{3,4}, MD, PD, FMER, FEBO
 Ugo Murialdo⁵, MD

- **Demyelinating diseases**
 - Multiple sclerosis
- Monosymptomatic optic neuritis
- **Infectious diseases**
 - Viral (herpes virus, cytomegalovirus, West Nile virus, human T-cell lymphotropic virus (HTLV-1), acquired immunodeficiency syndrome (AIDS), subacute sclerosing panencephalitis (SSPE))
 - Bacterial (cat-scratch disease, Whipple's disease)
 - Mycobacterial (tuberculosis, leprosy)
 - Spirochetal (Lyme, syphilis)
 - Protozoal (toxoplasmosis, pneumocystis carinii)
 - Nematodal or parasitic (gnathostomiasis)
- **Inflammatory or Autoimmune**
 - Polyarteritis nodosa
 - Wegener granulomatosis
 - Rheumatoid arthritis and
 - Sarcoidosis
 - Behçet's disease
 - VKH disease
 - APMPPE (acute posterior multifocal placoid pigment epitheliopathy)
 - **Neoplastic**
 - Lymphoma
 - Paraneoplastic syndromes

J Neurol (2014) 261:1662–1676
 DOI 10.1007/s00415-013-7209-3

REVIEW

Diagnosis and management of Neuro-Behçet's disease: international consensus recommendations

Seema Kalra · Alan Silman · Gulsen Akman-Demir · Saeed Bohlega · Afshin Borhani-Haghighi ·
 Cris S. Constantinescu · Habib Houman · Alfred Mahr · Carlos Salvarani ·
 Petros P. Sfikakis · Aksel Siva · Adnan Al-Araji

International consensus recommendation (ICR) criteria for NeuroBehcet disease (NBD) diagnosis

• Definite NBD

1. Satisfy the ISG criteria for BD
2. Neurological syndrome supported by :
 - a. Neuroimaging
 - b. CSF
3. No better explanation for the neurological findings

• Probable NBD

1. Neurological syndrome with systemic BD but not satisfying the ISG criteria
2. A non-characteristic neurological syndrome occurring in the context of ISG criteria-supported BD

International consensus recommendation (ICR) criteria for NeuroBehcet disease (NBD) diagnosis

- **Definite NBD**

1. **Satisfy the ISG criteria for BD**
2. Neurological syndrome supported by :
 - a. Neuroimaging
 - b. CSF
3. No better explanation for the neurological findings

- **Probable NBD**

1. Neurological syndrome with systemic BD but not satisfying the ISG criteria
2. A non-characteristic neurological syndrome occurring in the context of ISG criteria-supported BD

ISCBD

Recurrent oral ulceration (obligatory)	minor aphthous, major aphthous, or herpetiform ulceration (observed by physician or patient); recurring at least 3 times in one 12-month period
<i>Plus 2 of</i>	
Recurrent genital ulceration	aphthous ulceration or scarring (observed by physician or patient)
Eye lesions	anterior uveitis, posterior uveitis, or cells in vitreous on slit lamp examination; or retinal vasculitis observed by ophthalmologist
Skin lesions	erythema nodosum (observed by physician or patient), pseudofolliculitis, or papulopustular lesions; or acneiform nodules (observed by physician) in post-adolescent patients not on corticosteroid treatment
Positive pathergy test	read by physician at 24–48 h
Findings applicable only in absence of other clinical explanations.	

International consensus recommendation (ICR) criteria for NeuroBehcet disease (NBD) diagnosis

- **Definite NBD**

1. Satisfy the ISG criteria for BD
2. **Neurological syndrome** supported by :
 - a. Neuroimaging
 - b. CSF
3. No better explanation for the neurological findings

- **Probable NBD**

1. Neurological syndrome with systemic BD but not satisfying the ISG criteria
2. A non-characteristic neurological syndrome occurring in the context of ISG criteria-supported BD

Recognised neurological syndromes

- **Parenchymal syndrome**

- Brainstem: ophthalmoparesis, cranial neuropathy, cerebellar or pyramidal dysfunction.
- Myelopathy.
- Cerebral: encephalopathy, hemiparesis, hemisensory loss, seizures and dysphasia, and mental changes.
- Optic neuropathy
- Multifocal

- **Non-parenchymal syndromes**

- Cerebral venous thrombosis
- Intracranial hypertension syndrome
- Intracranial aneurysm
- Acute meningeal syndrome

International consensus recommendation (ICR) criteria for NeuroBehcet disease (NBD) diagnosis

- **Definite NBD**


1. Satisfy the ISG criteria for BD
2. Neurological syndrome (with objective neurological signs) supported by :
 - a. **Neuroimaging**
 - b. CSF
3. No better explanation for the neurological findings

- **Probable NBD**

1. Neurological syndrome with systemic BD but not satisfying the ISG criteria
2. A non-characteristic neurological syndrome occurring in the context of ISG criteria-supported BD

Characteristic MRI findings in NBD


☐ Parenchymal NBD

Nature	Site	
<ul style="list-style-type: none"> • Acute : hypointense on T1, hyperintense on T2 • Chronic: non-enhancing, atrophy esp. brain stem 	<ul style="list-style-type: none"> • Brain stem • Cerebral: subcortical, paraventricular 	

Characteristic MRI findings in NBD

□ Non-parenchymal NBD

- MR venography shows cerebral sinus or vein thrombosis.
- Normal appearances are seen in IIH.
- Meningeal enhancement is seen in acute meningeal syndrome.



International consensus recommendation (ICR) criteria for NeuroBehcet disease (NBD) diagnosis

• Definite NBD

1. Satisfy the ISG criteria for BD
2. Neurological syndrome (with objective neurological signs) supported by :
 - a. Neuroimaging
 - b. CSF**
3. No better explanation for the neurological findings

• Probable NBD

1. Neurological syndrome with systemic BD but not satisfying the ISG criteria
2. A non-characteristic neurological syndrome occurring in the context of ISG criteria-supported BD

Characteristic CSF finding

- Increased cells
- Increased proteins
- High IL-6

International consensus recommendation (ICR) criteria for NeuroBehcet disease (NBD) diagnosis

- **Definite NBD**

1. Satisfy the ISG criteria for BD
2. Neurological syndrome (with objective neurological signs) supported by :
 - a. Neuroimaging
 - b. CSF

- 3. No better explanation for the neurological findings**

- **Probable NBD**

1. Neurological syndrome with systemic BD but not satisfying the ISG criteria
2. A non-characteristic neurological syndrome occurring in the context of ISG criteria-supported BD

Specific conditions to be excluded:

- Multiple sclerosis
- Stroke affecting the young
- Intracranial hypertension
- Meningo-encephalitis
- Myelitis
- Uveo-meningitic syndromes including sarcoidosis, systemic lupus erythematosus, and primary Sjögren's syndrome
- CNS neoplasms i.e lymphoma
- Neurological complications of therapies for BD

NBD vs MS

Clinical	CSF	MRI
<ul style="list-style-type: none"> sensory presentation, optic neuritis, internuclear ophthalmoplegia, limb ataxia, and cerebellar dysarthria 	<ul style="list-style-type: none"> Oligoclonal bands 	<ul style="list-style-type: none"> Periventricular
<ul style="list-style-type: none"> headaches, motor symptoms, pseudobulbar speech and cognitive-behavioral 	<ul style="list-style-type: none"> more cells 	<ul style="list-style-type: none"> Subcortical Brain stem atrophy

IL-6

- Serum IL-6 levels have been reported to correlate with BD disease activity, although this finding has not been consistently reproduced.

HLA-B51/5

- In addition, the prevalence of HLA-B51/B5 among subjects with NBD is not dissimilar to that found in patients with BD without neurological involvement

Treatment

- **IV** methyl prednisolone for 3–10 days followed by a maintenance oral steroids.
- **Azathioprine** a first-line DMT; mycophenolate mofetil, methotrexate, and cyclophosphamide.
- **Biologics** (infliximab, adalimumab, etanercept) or interferon alpha, when first line therapies are ineffective or intolerable.

- **Cyclosporin** in BD patients ?????
 - ✓ potential association with neurological complications.
 - ✓ avoided in patients with a history of NBD.
 - ✓ should be stopped when BD patients develop neurological features.
- **Anticoagulants**, which is a standard treatment of CVT of any aetiology. ?????
 - ✓ caution should be taken to rule-out a systemic aneurysm

- A 36 year old male diagnosed as Behçet (orogenital ulcers and uveitis)
- Presenting with emotional liability and personality changes.
- History of acute attack of LL weakness 1 year ago, & convulsions & bulbar symptoms 3 years ago.
- Was on pulse steroids then On cyclophosphamide monthly and shifted to azathioprine 4 months ago.


- MRI, MRV, MRA:
 - ✓ Variable sized foci of abnormal signals in both frontal & parietal lobes.(mostly **vasculitic**)
 - ✓ Brain **atrophic** changes
 - ✓ **Occluded** sigmoid and transverse sinuses.



- Psychiatric consultation:
Old frontal lobe lesions

Ophthalmological consultation:

- Vision: 6/12 6/9
- AC cells: +0.5 +1
- Pupil: RAPD RRR
- Fundus: vitreous cell
 pale disc temporal pallor
 sheathed attenuated vessels
 blunt foveal reflex



- MRI, MRV & MRA:
 - ✓ Stationary course regarding atrophic brain changes and frontoparietal insults
 - ✓ Occluded sigmoid and transverse sinuses.



- VKH is characterized by bilateral diffuse choroiditis with exudative retinal detachment.
- In addition to visual loss, the presence of hearing loss, tinnitus, poliosis, vitiligo, or meningismus could be helpful for the diagnosis.
- However, in cases that show only marked bilateral optic disc edema without any signs or symptoms, it could be difficult to consider VKH, and other conditions such as elevated blood pressure/intracranial pressure and inflammation or infection may be considered in the DD.

Int Ophthalmol (2007) 27:217–220
DOI 10.1007/s10792-006-9026-5

CASE REPORT

Vogt–Koyanagi–Harada disease presenting as optic neuritis

Ranjan Rajendram · Monica Evans ·
Rahul N. Khurana · Julie H. Tsai ·
Narsing A. Rao

- In the acute uveitic stage of VKH disease choroiditis may cause **papillitis**, which is similar to optic neuritis.
- VKH should be considered in the DD of bilateral optic disc swelling, even in the absence of the characteristic extraocular manifestations.

Clinical and Epidemiologic Research

Optic Disc Swelling in Vogt-Koyanagi-Harada Disease

Kumiko Nakao, Noriko Abematsu, Yuka Mizusbima, and Taiji Sakamoto


IOVS, April 2012, Vol. 53, No. 4

- VKH patients who had disc swelling have developed irreversible visual **field defects**.
- FFA showed both a **filling delay** and late leakage of the optic disc.
- Subsequently, the optic disc developed **pallor**, and the retinal nerve fiber layer thickness decreased.
- These findings suggest that **AION** developed nearly simultaneously with VKH.

Bilateral disc edema in a patient with Vogt-Koyanagi-Harada disease

Can J Ophthalmol 2014;49:e52-e54

- In some patients serous RD is not remarkable, but optic disc swelling and mild retinal folds can be observed on fundus examination.



Am J Ophthalmol (2013) 99:103-108
 DOI: 10.1007/s10094-014-0007-0

THE OFFICIAL JOURNAL OF THE JAPANESE OPHTHALMOLOGICAL SOCIETY


CLINICAL INVESTIGATION

Differences in the clinical features of two types of Vogt-Koyanagi-Harada disease: serous retinal detachment and optic disc swelling

Yoko Ohnuki · Kinya Tsubota · Takashi Kozuka · Hiroshi Goto


RD-type VKH disease

- Patients with clinically evident serous RD detected by OCT and FA with or without OD swelling.



OD swelling-type VKH disease.

- Patients with clinically evident OD hyperemia and swelling with no or minimal detectable serous RD on OCT




- A 31 year old female came complaining of bilateral sudden painless diminution of vision of 2 days duration.
- She said that she had a severe headache & blurring of vision 10 days before for which she sought medical advice.
- CT brain was done & Lumbar puncture.
- She was on cidamex tablets.


- Visual acuity
 - ✓ Rt eye PLBP
 - ✓ Lt eye HMGP
- Pupillary reaction
 - ✓ bilateral sluggish reactive

Fundus examination

- Showed bilateral disc swelling with total exudative RD & vitritis




Anterior segment




- The patient was given bilateral subtenon steroid injection.
 - Medical treatment in the form of corticosteroids 60 mg per day
 - Azathioprine
-
- 10 days after the treatment
 - ✓ Rt eye CF 80 cm
 - ✓ Lt eye 2/60
-
- One month after the treatment
 - ✓ Rt eye 6/36
 - ✓ Lt eye..... 6/24

Prognosis



Prognosis



Take home message

- Neurological symptoms are not rare in patients with uveitic syndromes.
- They can be used as a guide to diagnosis.
- Some of the findings are nonspecific, but others can be typical.

References

- Okunuki Y, Tsubota K, Kezuka T, Goto H. Differences in the clinical features of two types of Vogt-Koyanagi-Harada disease: serous retinal detachment and optic disc swelling. *Jpn J Ophthalmol*. 2015;59:103e108.
- Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. *Am J Ophthalmol*. 2001;131:647e652.
- Kazuichi Maruyama, Aya Noguchi, Ai Shimizu, Yukihiro Shiga, Hiroshi Kunikata, Toru Nakazawa. Predictors of Recurrence in Vogt-Koyanagi-Harada Disease. *Ophthalmology Retina* 2017;:-1e8
- Ranjan Rajendram Æ Monica Evans Æ Rahul N. Khurana Æ Julie H. Tsai Æ Narsing A. Rao. Vogt-Koyanagi-Harada disease presenting as optic neuritis. *Int Ophthalmol* (2007) 27:217-220
- Kumiko Nakao, Noriko Abematsu, Yuka Mizushima, and Taiji Sakamoto. Optic Disc Swelling in Vogt-Koyanagi-Harada Disease. *Invest Ophthalmol Vis Sci*. 2012;53:1917-1922
- Caruso P, Moretti R. Focus on neuro-Behçet's disease: A review. *Neurol India* 2018;66:1619-28

